Current Report Filing (8-k)
November 04 2021 - 06:47AM
Edgar (US Regulatory)
0001589150 false 0001589150 2021-10-12
2021-10-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): October
12, 2021
REGEN BIOPHARMA, INC.
(Exact name of small business issuer as specified in its
charter)
Nevada |
45-5192997 |
(State or
other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) |
Commission File No. 333-191725
4700 Spring Street,
St 304,
La Mesa,
California
91942
(Address of Principal Executive Offices)
(619)
722 5505
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title of
each class |
|
Trading
Symbol(s) |
|
Name of
each exchange on which registered |
|
|
None |
|
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.☐
Item 8.01 Other Events.
On October 12, 2021 the United States Patent and Trademark Office (
“USPTO”) issued Patent Number 11,141,471 B2 to Regen Biopharma,
Inc. for “UNIVERSAL DONOR CHECKPOINT INHIBITOR SILENCED/GENE
EDITED CORD BLOOD KILLER CELLS”
The invention encompasses compositions of matters, cells, and
treatment protocols useful for induction of anticancer responses in
a patient suffering from cancer. In one embodiment the invention
provides the use of NR2F6 silencing or gene editing in cord blood
cells possessing anti-tumor activity in order to induce potentiated
killer cells suitable for therapeutic use. In one embodiment said
allogeneic cord blood killer cells are administered to initiate a
cascade of antitumor immune responses, with initially responses
mediated by allogeneic killer cells, and followed by endogenous
immune responses.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
REGEN BIOPHARMA,
INC. |
|
|
Dated:
November 4, 2021 |
By: /s/ David
Koos |
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Apr 2022 to May 2022
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From May 2021 to May 2022